Alosetron
| Code | Size | Price |
|---|
| TAR-T21235-200mg | 200mg | £1,033.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Alosetron, a 5-HT3 antagonist, is used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in women only.
CAS:
122852-42-0
Formula:
C17H18N4O
Molecular Weight:
294.358
Purity:
0.98
SMILES:
Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C
References
1. Motavallian A, Minaiyan M, Rabbani M, Mahzouni P, Andalib S. Anti-inflammatory effects of alosetron mediated through 5-HT(3) receptors on experimental colitis. Res Pharm Sci. 2019 Jun;14(3):228-236. doi: 10.4103/1735-5362.258489. PubMed PMID: 31160900; PubMed Central PMCID: PMC6540920.
2. Olden KW, Chey WD, Shringarpure R, Paul Nicandro J, Chuang E, Earnest DL. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Curr Med Res Opin. 2019 Mar;35(3):461-472. doi: 10.1080/03007995.2018.1533456. Epub 2018 Nov 22. PubMed PMID: 30293448.
3. Lacy BE, Nicandro JP, Chuang E, Earnest DL. Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint. Therap Adv Gastroenterol. 2018 May 8;11:1756284818771674. doi: 10.1177/1756284818771674. eCollection 2018. PubMed PMID: 29774051; PubMed Central PMCID: PMC5949923.